JET2019

講演情報

Presentation Awards

[L2-9] Presentation Awards

Heat-14 Femoropopliteal, clinical trials

2019年2月23日(土) 14:50 〜 16:20 HallL-2 (Nexus)

Moderator: Su Hong Kim(Busan Veterans Hospital),Tatsuya Nakama(Tokyo Bay Medical Center)
Panelist: Yo Iwata(Funabashi Municipal Medical Center),Chunshui He(Teaching hospital of Chengdu University of Traditional Chinese Medicine)

[MO-92] Treatment strategy of femoropopliteal lesions with drug-coated balloons by vascular surgeons

Daisuke Akagi (Tokyo Metropolitan Geriatric Medical Center, Department of Vascular Surgery)

【Purpose】For treatment of femoropopliteal (FP) lesions drug-coated balloons (DCB) were widely available for half a year in Japan. It is very difficult to remove occluded stents. To leave more options for revisions during long prognosis, we adopt it is good to treat without stents if possible. So for treatments of FP lesions usage of DCB were considered first of all. We gently inflate balloons to avoid dissections for DCB usage. In this paper we show our results after DCB were launched to discuss proper usage of DCB. 【Patients and methods】From April 2018 to November 2018, 51 cases (69 limbs, average 76 years old) for PAD with FP lesions were recruited. Intermittent caludications (IC) were 51 limbs and critical limb ischemia (CLI) were 18 limbs. Outpatient follow-up of treated lesions with ultrasound were performed at leat every 3 months.【Results】DCB were used 39 limbs (56%). All EVTs for IC were achieved technically. In one case with a CTO occlusion occurred soon after the procedure with DCB. In other cases no TLR were experienced. One case needed bail-out stenting after DCB treatment because of dissection. Stent-graft viabahn were used 16 limbs and all viabahn were patent. In stent restenosis (ISR) for previously placed stents were 7 limbs and 4 cases were treated with viabahn.【Conclusions】Our early results with DCB-based strategy were satisfactory. We also analyze cases in which DCB cannot be used and discuss real indications of DCB in detail.